

# Multiple-Clones of Group-B Streptococci Clinical Isolates with an Unusual Erythromycin-Susceptible and Clindamycin-Resistant Phenotype



IALONARDI F(1), FACCONI D (1), ABEL S (1), MACHAIN M (2), ERRECALDE L (3), LITVIK A (4), KAUFFMAN S (3), MELANO R (5, 6), GALAS M (1), WHONET-ARGENTINA GROUP (WHO-ARG), CORSO A (1)

Email: [acorso@anlis.gov.ar](mailto:acorso@anlis.gov.ar)

(1) Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas (INEI)-ANLIS "Dr. C Malbrán", Buenos Aires; (2) HIGA Hosp Dr. Piñeyro (PYR), prov. Buenos Aires; (3) Hosp. Fernandez (FER), Buenos Aires; (4) Hosp. G. Rawson (RAW), prov. Córdoba, Argentina; (5) Ontario Public Health Lab, Toronto, Canada (6) Dep. of Lab. Medicine and Pathobiol, Univ of Toronto, Toronto, Canada.

## INTRODUCTION

Group-B Streptococci (GBS) is a common cause of neonatal diseases such as sepsis and meningitis. Macrolides are the recommended second-line agents and therapeutic alternative for mothers with a penicillin allergy.

Through the National Surveillance (WHO-ARG, 70 Hosp) we detected an increase in the resistance to erythromycin (ERY) and clindamycin (CLI) from 7.2% and 3% in 2005 to 12.8% and 5.7% in 2007.

Resistance to lincosamides in GBS is most commonly mediated by *Erm*-type methylases, but ribosomal mutations and *Lnu*-type nucleotidyl-transferases were also described. *LnuB* enzyme was only described in 3 GBS worldwide, 2 from Canada and 1 from the US.

During 2006-2008, six GBS expressing an unusual ERY susceptibility and CLI resistance (L-phenotype) by disc diffusion were submitted to the National Reference Laboratory (INEI) for molecular characterization.

**Clinical Strains.** Six GBS from 3 hospitals (PYR, RAW and FER) from 3 different cities displaying an L-phenotype were recovered from recto-vaginal screening culture. Isolates were submitted to the National Reference Laboratory (INEI) for further molecular characterization.

**Susceptibility assays.** Disc diffusion and Minimal Inhibitory Concentrations by agar dilution method was performed and interpreted according CLSI guidelines.

**PCR amplification.** PCR was performed under standard conditions and detection of *ermA*, *ermB*, *InuA*, *InuB* and *InuC* genes was carried out using primers described (Bozdogan B. AAC 43:925-9, 1999; Lina G. AAC 43:1062-6, 1999; Sutcliffe J. AAC 40:2562-6 1996).

**DNA sequencing.** *InuB* gene was sequenced using BigDye terminator system.

**Conjugation assay.** *S. agalactiae* M6395 (susceptible to macrolide and lincosamides but resistant to fluoroquinolone) and *Staphylococcus aureus* RN4220 were used as recipient strains. A ratio 1:5 of donor:recipient strains were assayed. Selection plates of BHI agar plus blood were incubated in CO<sub>2</sub> ambient.

**Molecular typing.** Genomic DNA was digested with *Apal* enzyme and DNA fragments were separated on 1% agarose gel at 6 V/cm during 20 h and using 2 and 20 sec as initial and final switch time respectively. PFGE DNA patterns were analyzed using Tenover's criteria (Tenover F., et al. JCM (1995) 33:2233-9).

## OBJECTIVE

The objective of this work was to characterize the mechanism of resistance and to evaluate the relationship between these isolates.

FIGURE 1.




Figure 1. Disc diffusion assay of a representative SGB, M6642, showing susceptibility to PEN, CTX and ERY, and resistance to CLI and LIN.

TABLE.

Isolate	Disk Diffusion Interpretation						MIC (µg/ml)			Resistance Phenotype								
	PEN	CTX	TET	OFX	LXV	VAN	ERY	CLI	LIN									
M6390	S	S	I	S	S	S	S	R	R	0,06	S	0,25	S	64	R	4	R	L
M6637	S	S	I	S	S	S	S	R	R	0,12	S	0,25	S	128	R	4	R	L
M6639	S	S	S	S	S	S	S	R	R	0,06	S	0,25	S	64	R	4	R	L
M6640	S	S	S	S	S	S	S	R	R	0,12	S	0,25	S	128	R	4	R	L
M6641	S	S	I	S	S	S	S	R	R	0,12	S	0,25	S	128	R	4	R	L
M6642	S	S	S	S	S	S	S	R	R	0,12	S	0,25	S	128	R	4	R	L

Antibiotics tested: penicillin (PEN); cefotaxime (CTX); tetracycline (TET); ofloxacin (OFX); levofloxacin (LXV); vancomycin (VAN); erythromycin (ERY); azithromycin (AZM); clindamycin (CLI); lincomycin (LIN). L-Phenotype: ERY-susceptible and CLI-resistant.

## RESULTS

- All six GBS were susceptible to β-lactams (penicillin and cefotaxime), fluoroquinolones (ofloxacin and levofloxacin), and vancomycin. Three isolates were intermediate to tetracycline (Table).
- By disc diffusion the strains showed susceptibility to erythromycin but not zone for clindamycin and lincomycin (Figure 1).
- GBS isolates were susceptible to ERY (≤ 0.12 mg/L) and azithromycin (≤ 0.25 mg/L), and resistant to CLI (4 mg/L) and lincomycin (64-128 mg/L).
- All six isolates were positive for *InuB* gene, and negative for *Erm*-methylases (*ermA* and *ermB*) and others *Inu* genes (*InuA* and *InuC*).
- *InuB* sequence was confirmed by sequencing.
- Conjugation assays using *S. agalactiae* and *Staphylococcus aureus* as recipient strains were unsuccessful.
- Four clones were discriminated using *Apal*-PFGE: Clone A (3 strains) was detected in FER hospital, and the remaining were from PYR (clone B), RAW (clone C) and FER (clone D) hospitals (Figure 2).

FIGURE 2. *Apal*-PFGE




Figure 2. *Apal*-PFGE of *S. agalactiae* genomic DNA. Lanes M, PFG marker; line 1, M6390; 2, M6637; 3, M6639; 4, M6640; 5, M6641; 6, M6642.

## CONCLUSIONS

- 1) The L-phenotype was associated with the presence of *InuB* gene.
- 2) The emergence of SGB harboring the *InuB* gene was polyclonal and was not transferable.
- 3) The continuous surveillance of the antibiotic susceptibility of GBS is necessary; not only to detect known resistance phenotypes, but also to identify newly acquired resistance mechanisms.